Liver transplantation for the treatment of hepatocellular carcinoma.
- Author:
Xin-guo CHEN
1
;
Xiao-dan ZHU
;
Wei LI
;
Yu LIU
;
Wei-long ZOU
;
Yu-jian NIU
;
Feng-dong WU
;
Zhao-jie GUAN
;
Yang YUE
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Carcinoma, Hepatocellular; pathology; surgery; Female; Follow-Up Studies; Humans; Liver Neoplasms; pathology; surgery; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Retrospective Studies; Survival Analysis; Treatment Outcome
- From: Chinese Journal of Oncology 2006;28(8):628-631
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo retrospectively evaluate the clinical outcomes of liver transplantation for patients with hepatocellular carcinoma (HCC).
METHODSThe clinical data of 88 consecutive HCC patients who underwent orthotopic liver transplantation between 2002. 4 and 2004. 7 were retrospectively reviewed. HCC stage of those patients were defined according to the pTNM classification system of UICC. All patients were followed up for more than 12 months after liver transplantation. The recurrence and overall survival rate were evaluated by univariate and multivariate analysis with SAS software.
RESULTSThe cumulative 1-year recurrence rate of stage I, II, III and IV after liver transplantation was 0%, 4.8%, 40.0% and 71.3%, respectively (P < 0.01). The cumulative 1-year overall survival rate of stage I, II, III and IV was 100%, 95.2%, 71.5% and 41.7%, respectively (P < 0.01).
CONCLUSIONLiver transplantation may be suitable for stage I or II hepatocellular cancer patients and improve their prognosis, while it is not suitable for stage IV HCC patients.
